C.R. Bard, Inc.
730 Central Avenue, Murray Hill, NJ 07974
(908) 277-8000
www.crbard.com
Established: 1907
Number of employees: almost 12,000
Nature of business: C. R. Bard, Inc. (NYSE: BCR) is a leading multinational developer, manufacturer, and marketer of innovative, life-enhancing medical technologies in the fields of Vascular, Urology, Oncology, and Surgical Specialty products. Bard markets its products and services worldwide to hospitals, individual health care professionals, extended care facilities, and alternate site facilities. Bard has been a public company since 1963 and a member of the New York Stock Exchange since 1968.
Chief Executives:
- Timothy M. Ring, Chairman, Chief Executive Officer
- John H. Weiland, President, Chief Operating Officer
- Todd C. Schermerhorn, Senior Vice President, Chief Financial Officer
Locations: Headquartered in Murray Hill, New Jersey, Bard serves healthcare providers through five divisions:
- Bard Access Systems, Inc. (Salt Lake City, UT)
- Bard Electrophysiology Division (Lowell, MA)
- Bard Medical Division (Covington, GA)
- Davol Inc. (Warwick, RI)
- Bard Peripheral Vascular, Inc. (Tempe, AZ)
Overall, Bard has 50 locations in 28 different countries and Puerto Rico.
Innovation: Bard has introduced many “firsts” to the market, including the first: Foley catheter, arterial prosthesis, electrophysiology catheter and angioplasty catheter. Bard pioneered the development of single-patient-use medical products for hospital procedures. Today Bard is dedicated to pursuing technological innovations that offer superior clinical benefits while helping to reduce overall costs.
Community: Philanthropy has been part of Bard’s culture since the company’s inception. In 2010, the Bard Foundation, Corporate headquarters, U.S. Divisions and International cash grants totaled over $3.2 million, and employees around the world worked over 13,000 hours on more than 300 volunteer projects.
